- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 5.1 EX-5.1
- 8.1 EX-8.1
- 8.2 EX-8.2
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 10.29 EX-10.29
- 10.30 EX-10.30
- 10.31 EX-10.31
- 10.32 EX-10.32
- 10.33 EX-10.33
- 10.34 EX-10.34
- 10.35 EX-10.35
- 10.36 EX-10.36
- 10.39 EX-10.39
- 10.40 EX-10.40
- 10.41 EX-10.41
- 10.42 EX-10.42
- 10.43 EX-10.43
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.4 EX-99.4
- 25 Feb 20 EFFECT Notice of effectiveness
- 24 Feb 20 424B3 Prospectus supplement
- 20 Feb 20 S-4/A Registration of securities issued in business combination transactions (amended)
- 13 Feb 20 S-4/A Registration of securities issued in business combination transactions (amended)
- 29 Jan 20 S-4/A Registration of securities issued in business combination transactions (amended)
-
23 Dec 19 S-4 Registration of securities issued in business combination transactions
- 20 Feb 20 Registration of securities issued in business combination transactions (amended)
- 13 Feb 20 Registration of securities issued in business combination transactions (amended)
- 29 Jan 20 Registration of securities issued in business combination transactions (amended)
- 23 Dec 19 Registration of securities issued in business combination transactions
Exhibit 99.4
Special Committee of the Board of Directors
Organovo Holdings, Inc.
440 Stevens Avenue, Suite 200
Solana Beach, California 92075
We hereby consent to the inclusion of our opinion letter, dated December 12, 2019, to the Special Committee of the Board of Directors of Organovo Holdings, Inc. (the “Company”), as Annex B to, and reference to such opinion letter under the headings “Prospectus Summary — Opinion of Organovo’s Special Committee’s Financial Advisor” and “The Merger — Opinion of Organovo’s Special Committee’s Financial Advisor” in, the proxy statement/prospectus relating to the proposed merger involving the Company and Tarveda Therapeutics, Inc., which proxy statement/prospectus statement forms a part of the Registration Statement onForm S-4 of the Company (the “Registration Statement”). By giving such consent, we do not thereby admit that we are experts with respect to any part of such Registration Statement within the meaning of the term “expert” as used in, or that we come within the category of persons whose consent is required under, the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.
Very truly yours,
/s/ ROTH CAPITAL PARTNERS, LLC
ROTH CAPITAL PARTNERS, LLC
December 23, 2019